GlassScriptPhysician profile
Paul C Pedersen
NPI 1003892720
$6,205.10
in general payments reported to CMS, 2019-2025
35 companies · $507 in 2025
The $507 reported for 2025 was more than what 84% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $763 · 2021: $1,111 · 2022: $300 · 2023: $947 · 2024: $1,130 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $807.22 | 2019-2025 | Farxiga, Breztri |
| Pfizer INC. | $677.33 | 2019-2025 | |
| Novo Nordisk INC | $529.20 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $422.36 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $401.96 | 2019-2022 | |
| Lilly USA, LLC | $386.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $333.22 | 2019-2024 | |
| Amarin Pharma, INC. | $332.56 | 2019-2022 | |
| Abbvie INC. | $288.66 | 2020-2025 | |
| Amgen INC. | $220.43 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $212.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.27 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.74 | 2023-2025 | |
| Glaxosmithkline, LLC. | $168.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $118.47 | 2019-2021 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Pedersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.